PriceTargets.com logo

bioAffinity Technologies - BIAF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 504.35%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.99 As of 12/20/2024 06:31 PM ET
▼ -0.1872 (-15.86%)

This chart shows the closing price for BIAF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New bioAffinity Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIAF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIAF

Analyst Price Target is $6.00
▲ +504.35% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for bioAffinity Technologies in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 504.35% upside from the last price of $0.99.

This chart shows the closing price for BIAF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in bioAffinity Technologies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/23/2024Maxim GroupInitiated CoverageBuy$6.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
bioAffinity Technologies logo
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Read More

Today's Range

Now: $0.99
Low: $0.98
High: $1.29

50 Day Range

MA: $1.29
Low: $0.88
High: $2.18

52 Week Range

Now: $0.99
Low: $0.83
High: $3.62

Volume

478,568 shs

Average Volume

140,180 shs

Market Capitalization

$15.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.85

Frequently Asked Questions

What sell-side analysts currently cover shares of bioAffinity Technologies?

The following Wall Street research analysts have issued reports on bioAffinity Technologies in the last year: Maxim Group.
View the latest analyst ratings for BIAF.

What is the current price target for bioAffinity Technologies?

0 Wall Street analysts have set twelve-month price targets for bioAffinity Technologies in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 504.4%. Maxim Group has the highest price target set, predicting BIAF will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for bioAffinity Technologies in the next year.
View the latest price targets for BIAF.

What is the current consensus analyst rating for bioAffinity Technologies?

bioAffinity Technologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIAF will outperform the market and that investors should add to their positions of bioAffinity Technologies.
View the latest ratings for BIAF.

What other companies compete with bioAffinity Technologies?

Other companies that are similar to bioAffinity Technologies include Junee, Vivakor, Mobiquity Technologies, Inuvo and Fluent. Learn More about companies similar to bioAffinity Technologies.

How do I contact bioAffinity Technologies' investor relations team?

The company's listed phone number is 210-698-5334 and its investor relations email address is [email protected]. The official website for bioAffinity Technologies is www.bioaffinitytech.com. Learn More about contacing bioAffinity Technologies investor relations.